Showing 1 - 7 results of 7 for search 'Sender Herschorn', query time: 0.03s Refine Results
  1. 1
    Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database

    Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database by Christopher R. Chapple, Linda Cardozo, Robert Snijder, Emad Siddiqui, Sender Herschorn

    Published 2016-12-01
    Get full text
    Article
  2. 2
    Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

    Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter... by Sender Herschorn, David Staskin, Le Mai Tu, Jonathan Fialkov, Terry Walsh, Katherine Gooch, Carol R. Schermer

    Published 2018-04-01
    Get full text
    Article
  3. 3
    Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)

    Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR) by Tomas L. Griebling, Noll L. Campbell, Jeffrey Mangel, David Staskin, Sender Herschorn, Dina Elsouda, Carol R. Schermer

    Published 2020-03-01
    Get full text
    Article
  4. 4
    The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial

    The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results... by Jose E. Batista, Heinz Kölbl, Sender Herschorn, Tomasz Rechberger, Javier Cambronero, Michael Halaska, Alex Coppell, Mathilde Kaper, Moses Huang, Emad Siddiqui

    Published 2015-08-01
    Get full text
    Article
  5. 5
    Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study

    Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study by Rano Matta, Amanda E. Hird, Erind Dvorani, Refik Saskin, Gregory J. Nason, Girish Kulkarni, Ronald T. Kodama, Sender Herschorn, Robert K. Nam

    Published 2020-10-01
    Get full text
    Article
  6. 6
    Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

    Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies by Andrea Tubaro, José E. Batista, Victor W. Nitti, Sender Herschorn, Christopher R. Chapple, Mary Beth Blauwet, Emad Siddiqui, Moses Huang, Matthias Oelke

    Published 2017-06-01
    Get full text
    Article
  7. 7
    Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis

    Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis by Christopher J. D. Wallis MD, Gerard Morton MD, Angela Jerath MD, Raj Satkunasviam MD, Ewa Szumacher MD, Sender Herschorn MD, Ronald T. Kodama MD, Girish S. Kulkarni MD, David Naimark MD, Robert K. Nam MD

    Published 2017-05-01
    Get full text
    Article

Search Tools: